PBYI Live signals | Maximize Profits with Getagraph.com

BUY 101593 min ago

@ $7.35

Issued: 14 Feb 2024 @ 15:31

Return: -34.29%

Previous signal: Feb 13 - 15:35

Previous signal: Sell

Return: 18.17 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally...

Stats
Today's Volume	309 785
Average Volume	582 735
Market Cap	232.84M
EPS	$0 ( 2024-02-29 )
Next earnings date	( $-0.160 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	10.73
ATR14	$0.00700 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Auerbach Alan H	Buy	6 577	Common Stock
2024-03-15	Auerbach Alan H	Buy	9 047	Stock Option (Right to Buy)
2024-02-12	Wong Alvin F	Buy	43 307	Common Stock
2024-02-12	Wong Alvin F	Buy	59 946	Stock Option (Right to Buy)
2024-02-12	Nougues Maximo F	Buy	43 307	Common Stock

INSIDER POWER
69.64
Last 99 transactions
Buy: 2 879 886 \| Sell: 561 464

Volume Correlation

Long: -0.05 (neutral)

Short: 0.08 (neutral)

Signal:(51.958) Neutral

Puma Biotechnology Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Puma Biotechnology Inc Correlation - Currency/Commodity

0.78
( moderate )

0.66
( moderate )

0.00
( neutral )

0.72
( moderate )

0.44
( neutral )

-0.59
( weak negative )

Puma Biotechnology Inc Financials

Annual	2023
Revenue:	$235.64M
Gross Profit:	$172.96M (73.40 %)
EPS:	$0.460

Q4	2023
Revenue:	$72.18M
Gross Profit:	$47.86M (66.30 %)
EPS:	$0.260

Q3	2023
Revenue:	$56.12M
Gross Profit:	$42.83M (76.33 %)
EPS:	$0.120

Q2	2023
Revenue:	$54.57M
Gross Profit:	$42.71M (78.27 %)
EPS:	$0.0455

Financial Reports:

No articles found.

Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.